two-bear-capital
(3)
Sanavia Oncology Inc.
Sanavia Oncology is a New York-based biotech company developing next-generation cancer immunotherapies for patients who don't benefit from existing treatments. Its proprietary platform pairs high-throughput sequencing, single-molecule super-resolution microscopy, 3D protein modeling and artificial intelligence to discover novel, clinically relevant cancer-specific epitopes in drug-resistant tumors, then generates antibodies with atomic-level specificity to those targets. The company is building antibody drug conjugates (ADCs), bispecific T cell engagers (TCEs) and CAR-T therapies - led by its SANA-01 ADC - and is backed by Two Bear Capital.
Server Ertem
Server Ertem is the founder and CEO of Sanavia Oncology, a New York biotech developing antibody drug conjugates, T-cell engagers, and CAR-T therapies aimed at the roughly 80% of cancer patients whose tumors escape today's treatments. He built the company after a PhD in cancer cell biology at Weill Cornell, a postdoc at Memorial Sloan Kettering, and a Runway Startup Postdoc fellowship at Cornell Tech - stitching high-throughput cell biology, super-resolution microscopy, and machine learning into a platform designed to find cancer-specific epitopes on validated targets with atomic-level precision.
J. Seth Strattan
J. Seth Strattan, PhD is a General Partner at Two Bear Capital, a Whitefish, Montana-based venture capital firm investing at the crossroads of life sciences and technology. With a PhD in Structural Biology and a BA in Philosophy from Stanford University, Strattan spent years at Stanford building and leading the engineering and data science teams behind landmark genomics consortia - ENCODE, the Human Cell Atlas, and the International Human Epigenomics Consortium - before pivoting to back the founders tackling biology's hardest problems. He is based in Silicon Valley, leads Two Bear Capital's Menlo Park office, and splits his remaining time between Montana and a family farm in the Appalachian Mountains of Kentucky.